These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31963134)

  • 21. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients.
    Groeschel S; Kühl JS; Bley AE; Kehrer C; Weschke B; Döring M; Böhringer J; Schrum J; Santer R; Kohlschütter A; Krägeloh-Mann I; Müller I
    JAMA Neurol; 2016 Sep; 73(9):1133-40. PubMed ID: 27400410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hunter syndrome (Mucopolysaccharidosis type II), severe phenotype: long term follow-up on patients undergone to hematopoietic stem cell transplantation.
    Annibali R; Caponi L; Morganti A; Manna M; Gabrielli O; Ficcadenti A
    Minerva Pediatr; 2013 Oct; 65(5):487-96. PubMed ID: 24056375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapies for the bone in mucopolysaccharidoses.
    Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
    Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series.
    Selvanathan A; Ellaway C; Wilson C; Owens P; Shaw PJ; Bhattacharya K
    JIMD Rep; 2018; 41():81-89. PubMed ID: 29671225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
    Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
    Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucopolysaccharidoses and mucolipidoses.
    Wraith JE
    Handb Clin Neurol; 2013; 113():1723-9. PubMed ID: 23622395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral and craniofacial manifestations in a Hunter syndrome patient with hematopoietic stem cell transplantation: A case report.
    Torres RO; Pintor AVB; Guedes FR; Freitas-Fernandes LB; Barth AL; Horovitz DDG; de Souza IPR
    Spec Care Dentist; 2018 Jan; 38(1):51-54. PubMed ID: 29314214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age.
    Megens JH; de Wit M; van Hasselt PM; Boelens JJ; van der Werff DB; de Graaff JC
    Paediatr Anaesth; 2014 May; 24(5):521-7. PubMed ID: 24612129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study.
    Koehne T; Köhn A; Friedrich RE; Kordes U; Schinke T; Muschol N; Kahl-Nieke B
    Clin Oral Investig; 2018 Apr; 22(3):1541-1549. PubMed ID: 29046964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.
    Pal AR; Langereis EJ; Saif MA; Mercer J; Church HJ; Tylee KL; Wynn RF; Wijburg FA; Jones SA; Bruce IA; Bigger BW
    Orphanet J Rare Dis; 2015 Apr; 10():42. PubMed ID: 25887468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of ADL in patients with Hunter disease using FIM score.
    Kato T; Kato Z; Kuratsubo I; Ota T; Orii T; Kondo N; Suzuki Y
    Brain Dev; 2007 Jun; 29(5):298-305. PubMed ID: 17307320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management.
    Zhou J; Lin J; Leung WT; Wang L
    Intractable Rare Dis Res; 2020 Feb; 9(1):1-9. PubMed ID: 32201668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
    Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
    Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucopolysaccharidosis type II, Hunter's syndrome.
    Tylki-Szymańska A
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of 2 children with mucopolysaccharidosis by allogeneic hematopoietic stem cell transplantation].
    Chen J; Jiang H; Dong L; Wang Y; Luo C; Zhou M; Zhang W; Huang S; Gu X; Qiu W; Zhang H; Gu L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):675-7. PubMed ID: 19065530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of early haematopoietic stem cell transplantation versus enzyme replacement therapy on neurological progression in severe Hunter syndrome: Case report of siblings and literature review.
    Sreekantam S; Smith L; Stewart C; Kearney S; Lawson S; Raiman J; Vijay S; Santra S
    Mol Genet Metab Rep; 2022 Sep; 32():100881. PubMed ID: 35663302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M; Jones SA; Bonney D; Borrill RE; Coussons M; Mercer J; Bierings MB; Versluys B; van Hasselt PM; Wijburg FA; van der Ploeg AT; Wynn RF; Boelens JJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1106-9. PubMed ID: 25708213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II.
    Yokoi T; Yokoi K; Akiyama K; Higuchi T; Shimada Y; Kobayashi H; Sato T; Ohteki T; Otsu M; Nakauchi H; Ida H; Ohashi T
    Mol Genet Metab; 2016 Nov; 119(3):232-238. PubMed ID: 27590924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.